ANRIL has been shown to be a prognostic indicator of nasopharyngeal carcinoma, non-small-cell lung cancer, and epithelial ovarian cancer [37, 61]. The gene discussed is CDKN2B-AS1; the disease is non-small cell lung carcinoma.